267 related articles for article (PubMed ID: 29141806)
1. Marked neutropenia: Significant but rare in people with multiple sclerosis after alemtuzumab treatment.
Baker D; Giovannoni G; Schmierer K
Mult Scler Relat Disord; 2017 Nov; 18():181-183. PubMed ID: 29141806
[TBL] [Abstract][Full Text] [Related]
2. A case of Alemtuzumab-induced neutropenia in multiple sclerosis in association with the expansion of large granular lymphocytes.
Vakrakou AG; Tzanetakos D; Valsami S; Grigoriou E; Psarra K; Tzartos J; Anagnostouli M; Andreadou E; Evangelopoulos ME; Koutsis G; Chrysovitsanou C; Gialafos E; Dimitrakopoulos A; Stefanis L; Kilidireas C
BMC Neurol; 2018 Oct; 18(1):178. PubMed ID: 30373566
[TBL] [Abstract][Full Text] [Related]
3. Neutropenia with fatal outcome in a multiple sclerosis patient 23 days after alemtuzumab infusion.
Yiannopoulou KG; Papadimitriou D; Anastasiou AI; Siakantaris M
Mult Scler Relat Disord; 2018 Jul; 23():15-16. PubMed ID: 29730587
[TBL] [Abstract][Full Text] [Related]
4. Early neutropenia with thrombocytopenia following alemtuzumab treatment for multiple sclerosis: case report and review of literature.
Maniscalco GT; Cerillo I; Servillo G; Napolitano M; Guarcello G; Abate V; Improta G; Florio C
Clin Neurol Neurosurg; 2018 Dec; 175():134-136. PubMed ID: 30419425
[TBL] [Abstract][Full Text] [Related]
5. Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab.
Baker D; Herrod SS; Alvarez-Gonzalez C; Giovannoni G; Schmierer K
JAMA Neurol; 2017 Aug; 74(8):961-969. PubMed ID: 28604916
[TBL] [Abstract][Full Text] [Related]
6. Acute leukocytosis during alemtuzumab treatment in patients with active relapsing-remitting multiple sclerosis.
Iovino A; Aruta F; Carotenuto A; Manganelli F; Iodice R
Mult Scler Relat Disord; 2019 Feb; 28():98-100. PubMed ID: 30580038
[TBL] [Abstract][Full Text] [Related]
7. Neutropenia following immune-depletion, notably CD20 targeting, therapies in multiple sclerosis.
Baker D; Kang AS; Giovannoni G; Schmierer K
Mult Scler Relat Disord; 2024 Feb; 82():105400. PubMed ID: 38181696
[TBL] [Abstract][Full Text] [Related]
8. Alemtuzumab depletion failure can occur in multiple sclerosis.
Dubuisson N; Baker D; Kang AS; Pryce G; Marta M; Visser LH; Hofmann WE; Gnanapavan S; Giovannoni G; Schmierer K
Immunology; 2018 Jun; 154(2):253-260. PubMed ID: 29247512
[TBL] [Abstract][Full Text] [Related]
9. Hepatic microabscesses during CMV reactivation in a multiple sclerosis patient after alemtuzumab treatment.
Barone S; Scannapieco S; Torti C; Filippelli E; Pisani V; Granata A; Console D; Demonte G; Tallarico T; Polidoro S; Quattrone A; Valentino P
Mult Scler Relat Disord; 2018 Feb; 20():6-8. PubMed ID: 29272733
[TBL] [Abstract][Full Text] [Related]
10. Case Report: Delayed Alemtuzumab-Induced Concurrent Neutropenia and Thrombocytopenia in Relapsing-Remitting Multiple Sclerosis.
Ganju A; Stock JC; Jordan K
J Pharm Pract; 2023 Feb; 36(1):168-172. PubMed ID: 34169768
[TBL] [Abstract][Full Text] [Related]
11. Severe B cell-mediated disease activation despite two cycles of alemtuzumab in a patient with multiple sclerosis.
Hyun JW; Kim Y; Kim G; Kim SH; Kim HJ
Mult Scler; 2019 Dec; 25(14):1942-1945. PubMed ID: 30403365
[TBL] [Abstract][Full Text] [Related]
12. Pneumonitis secondary to alemtuzumab in a patient with multiple sclerosis - A non-infectious cause of breathlessness.
Whiteside D; Barth S; Datta A; Trip SA
Mult Scler Relat Disord; 2018 May; 22():139-140. PubMed ID: 29684788
[TBL] [Abstract][Full Text] [Related]
13. Life-threatening autoimmune warm hemolytic anemia following treatment for multiple sclerosis with alemtuzumab.
Meunier B; Rico A; Seguier J; Boutiere C; Ebbo M; Harle JR; Schleinitz N; Pelletier J
Mult Scler; 2018 May; 24(6):811-813. PubMed ID: 29359614
[TBL] [Abstract][Full Text] [Related]
14. Depletion of CD52-positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immune-tolerance promoting CD8 T-cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis.
von Kutzleben S; Pryce G; Giovannoni G; Baker D
Immunology; 2017 Apr; 150(4):444-455. PubMed ID: 27925187
[TBL] [Abstract][Full Text] [Related]
15. Monitoring and management of autoimmunity in multiple sclerosis patients treated with alemtuzumab: practical recommendations.
Devonshire V; Phillips R; Wass H; Da Roza G; Senior P
J Neurol; 2018 Nov; 265(11):2494-2505. PubMed ID: 29525836
[TBL] [Abstract][Full Text] [Related]
16. Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells.
Ceronie B; Jacobs BM; Baker D; Dubuisson N; Mao Z; Ammoscato F; Lock H; Longhurst HJ; Giovannoni G; Schmierer K
J Neurol; 2018 May; 265(5):1199-1209. PubMed ID: 29550884
[TBL] [Abstract][Full Text] [Related]
17. Myasthenia gravis following alemtuzumab therapy for multiple sclerosis.
Midaglia L; Gratacòs M; Caronna E; Raguer N; Sastre-Garriga J; Montalban X; Tintoré M
Neurology; 2018 Sep; 91(13):622-624. PubMed ID: 30143565
[No Abstract] [Full Text] [Related]
18. Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis.
Hersh CM; Cohen JA
Immunotherapy; 2014; 6(3):249-59. PubMed ID: 24762071
[TBL] [Abstract][Full Text] [Related]
19. Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis.
Arroyo González R; Kita M; Crayton H; Havrdova E; Margolin DH; Lake SL; Giovannoni G;
Mult Scler; 2017 Sep; 23(10):1367-1376. PubMed ID: 27885061
[TBL] [Abstract][Full Text] [Related]
20. Acute myocardial infarction associated with initial alemtuzumab infusion cycle in relapsing-remitting multiple sclerosis.
Romba MC; Newsome SD; McArthur JC
Mult Scler Relat Disord; 2019 Sep; 34():100-102. PubMed ID: 31252364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]